What is your role and contribution to SOLACE?
I am currently leading the Estonian lung cancer screening pilot study and contributing into national screening program implementation.
What is the current situation in your country, in terms of lung cancer screening?
In Estonia we are currently running a regional lung cancer screening pilot study with main aim to prove the effectiveness of systematic patient enrollment. During the first year we achieved a target group participation rate of 79%. In addition we compare the usability and effectiveness of two enrollment criteria (smoking versus PLCOm2012 risk score).
It is expected that in 2025, we will expand the lung cancer screening into a few other counties of Estonia and start using a mobile CT unit to perform screening low-dose CT scans.
What do you hope to achieve with SOLACE and what your message would be to other countries?
We hope to share our experience with participants enrollment and would like to contribute into lung cancer screening guideline development and implementation.
Why SOLACE is important to you?
There are many open questions in lung cancer screening. Together we can better define the optimal target group, screening interval, patient enrollment methodology and patient management strategies (including the management of incidental findings).
This project is co-funded under the EU4Health Programme 2021–2027 under grant agreement no. 101101187. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
